Business
Kalytera Announces Issuance of Second Patent Covering the Use of CBD in Graft Versus Host Disease
Kalytera Announces Issuance of Second Patent Covering the Use of CBD in Graft Versus Host Disease.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n \n Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the \"Company\" \n or \"Kalytera\") today announced that the U.S. Patent and \n Trademark Office (\"USPTO\") issued U.S. Patent No. 9,956,182 \n with claims covering the use of cannabidiol (\"CBD\") for the \n prevention and treatment of acute and chronic forms of graft versus host \n disease (\"GVHD\"). Kalytera has exclusive worldwide rights to \n this issued patent through an Exclusive License Agreement with MOR \n Research Applications, Ltd. of Israel (“Mor”).\n \n \n GVHD is a multisystem disorder that is a life-threatening complication \n commonly occurring after bone marrow transplant procedures. GVHD occurs \n when the transplanted donor cells attack the patient’s organs, including \n the skin, gastrointestinal tract, liver, lungs and eyes. GVHD is \n associated with acute and chronic illness, infections, disability, \n reduced quality of life and death.\n \n \n In November 2017, Kalytera announced that it had received notice from \n the USPTO that the application for this patent would be allowed. The \n issuance of this patent by the USPTO is the final step in the patent \n application process, and provides patent coverage to Kalytera for the \n use of CBD in the prevention and treatment of acute and chronic forms of \n GVHD through May 2034 under the Exclusive License Agreement with Mor.\n \n \n This is the second patent covering the use of CBD in GVHD that Kalytera \n has received in the past three weeks. On April 19, Kalytera announced \n that the USPTO had issued U.S. Patent No. 9,889,100 B2 with claims \n covering the use of CBD for the treatment of severe and refractory GVHD.\n \n \n “We are delighted by the issuance of this second patent for CBD in the \n treatment and prevention of GVHD,” said Robert Farrell, President and \n CEO of Kalytera. “We now have very strong intellectual property \n protection that will provide us with market exclusivity for the use of \n CBD in GVHD through early 2034.”\n \n \n Mr. Farrell went on to state that, “Our program for prevention of GVHD \n is in Phase 2 clinical testing, and later this year we will begin a \n Phase 3 pivotal registration study in the treatment of GVHD. With our \n GVHD program advancing into the final phases of clinical testing, we \n will ...